Xencor, Inc Increase (Decrease) in Deferred Revenue
Xencor, Inc (XNCR) reported Increase (Decrease) in Deferred Revenue of -$9.01 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-02-28
- Xencor, Inc increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$840.00K.
- Xencor, Inc increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$7.09M.
- Xencor, Inc increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$740.00K, a 100.88% decline year-over-year.
- Xencor, Inc increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was -$340.00K.
- Xencor, Inc increase (decrease) in deferred revenue for fiscal 2017 was -$9.01M, a 112.94% decline from fiscal 2016.
- Xencor, Inc increase (decrease) in deferred revenue for fiscal 2016 was $69.62M, a 138.11% increase from fiscal 2015.
- Xencor, Inc increase (decrease) in deferred revenue for fiscal 2015 was $29.24M.
- Xencor, Inc increase (decrease) in deferred revenue for fiscal 2014 was -$5.16M, a 342.64% decline from fiscal 2013.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$840.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$7.93M derived: sum of 2 quarters · filed 2018-02-28 | -$8.67M derived: sum of 3 quarters · filed 2018-02-28 | -$9.01M 10-K · filed 2018-02-28 |
| 2017-09-30 | -$7.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$7.83M derived: sum of 2 quarters · filed 2017-11-08 | -$8.17M 10-Q · filed 2017-11-08 | -$9.61M derived: sum of 4 quarters · filed 2018-02-28 |
| 2017-06-30 | -$740.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$1.08M 10-Q · filed 2017-08-07 | -$2.52M derived: sum of 3 quarters · filed 2018-02-28 | -$10.00M derived: sum of 4 quarters · filed 2018-02-28 |
| 2017-03-31 | -$340.00K 10-Q · filed 2017-05-10 | -$1.78M derived: sum of 2 quarters · filed 2018-02-28 | -$9.26M derived: sum of 3 quarters · filed 2018-02-28 | $75.23M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-12-31 | -$1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$8.92M derived: sum of 2 quarters · filed 2018-02-28 | $75.57M derived: sum of 3 quarters · filed 2018-02-28 | $69.62M 10-K · filed 2018-02-28 |
| 2016-09-30 | -$7.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $77.01M derived: sum of 2 quarters · filed 2017-11-08 | $71.06M 10-Q · filed 2017-11-08 | $56.30M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $84.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $78.54M 10-Q · filed 2017-08-07 | $63.79M derived: sum of 3 quarters · filed 2018-02-28 | $108.19M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | -$5.95M 10-Q · filed 2017-05-10 | -$20.71M derived: sum of 2 quarters · filed 2018-02-28 | $23.70M derived: sum of 3 quarters · filed 2018-02-28 | $23.38M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | -$14.76M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $29.65M derived: sum of 2 quarters · filed 2018-02-28 | $29.33M derived: sum of 3 quarters · filed 2018-02-28 | $29.24M 10-K · filed 2018-02-28 |
| 2015-09-30 | $44.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $44.08M derived: sum of 2 quarters · filed 2016-11-02 | $43.99M 10-Q · filed 2016-11-02 | $41.29M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$322.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$413.00K 10-Q · filed 2016-08-03 | -$3.12M derived: sum of 3 quarters · filed 2017-03-01 | -$3.96M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | -$91.00K 10-Q · filed 2016-05-02 | -$2.79M derived: sum of 2 quarters · filed 2017-03-01 | -$3.64M derived: sum of 3 quarters · filed 2017-03-01 | -$4.36M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$3.55M derived: sum of 2 quarters · filed 2017-03-01 | -$4.26M derived: sum of 3 quarters · filed 2017-03-01 | -$5.16M 10-K · filed 2017-03-01 |
| 2014-09-30 | -$849.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$1.56M derived: sum of 2 quarters · filed 2015-11-04 | -$2.45M 10-Q · filed 2015-11-04 | -$4.18M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-06-30 | -$713.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$1.60M 10-Q · filed 2015-08-05 | -$3.33M derived: sum of 3 quarters · filed 2016-03-08 | -$5.49M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-03-31 | -$892.00K 10-Q · filed 2015-05-05 | -$2.62M derived: sum of 2 quarters · filed 2016-03-08 | -$4.78M derived: sum of 3 quarters · filed 2016-03-08 | -$3.19M derived: sum of 4 quarters · filed 2016-03-08 |
| 2013-12-31 | -$1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | -$3.89M derived: sum of 2 quarters · filed 2016-03-08 | -$2.30M derived: sum of 3 quarters · filed 2016-03-08 | $2.13M 10-K · filed 2016-03-08 |
| 2013-09-30 | -$2.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$572.00K derived: sum of 2 quarters · filed 2014-11-10 | $3.85M 10-Q · filed 2014-11-10 | |
| 2013-06-30 | $1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | $6.01M 10-Q · filed 2014-08-01 | ||
| 2013-03-31 | $4.42M 10-Q · filed 2014-05-15 | |||
| 2012-12-31 | -$4.56M 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |